Drug Extends Survival in Patients with Drug-Resistant Prostate Cancer

A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression of prostate cancer.

Modern Prostate Cancer Treatment Options

There have been remarkable advances in the treatment of all cancers in the last twenty years, but for prostate cancer in particular, because it is rather a slow-growing one, particularly in the early . . .

New drug extends survival in patients with drug-resistant prostate cancer

( Howard Hughes Medical Institute ) A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, Phase III clinical trial show. Although MDV3100 is one of the first drugs to prolong survival in patients whose prostate cancer has become resistant to standard therapy, there was initially much skepticism in the pharmaceutical industry about whether ...

Medivation's Prostate Cancer Drug: Survival Benefit With Low Seizure Risk

SAN FRANCISCO (TheStreet) -- A researcher reconfirmed Tuesday the survival benefit for Medivation's MDV3100 in patients with advanced prostate cancer and said seizures attributed to the experimental drug came in at a low 0.6% in a late-stage clinical trial. Medivation receiving a clean safety report for MDV3100 has been a pressing item on the agenda of biotech investors since November when the ...

Medivation prostate cancer drug well-tolerated in trial

(Reuters) - Medivation Inc's experimental prostate cancer pill caused fewer serious side effects in clinical trial patients than a placebo treatment, according to full results from a pivotal study announced on Tuesday. The news sent shares of Medivation up more than 11 percent to $61.75 in after-hours trading. Medivation and partner Astellas Pharma Inc reported in November that the trial had ...